Susha Cheriyedath

Feature Writer

B.Sc Chemistry, M.Sc. Biochemistry

Susha is a scientific communication professional holding a Master's degree in Biochemistry, with expertise in Microbiology, Physiology, Biotechnology, and Nutrition. After a two-year tenure as a lecturer from 2000 to 2002, where she mentored undergraduates studying Biochemistry, she transitioned into editorial roles within scientific publishing. She has accumulated nearly two decades of experience in medical communication, assuming diverse roles in research, writing, editing, and editorial management.

Passionate about health and nutrition, Susha is interested in various diet types, such as veganism, and their impact on the body and metabolism. She remains dedicated to staying current with the latest developments in the medical and health science fields. In her leisure time, she engages in gardening, cooking/baking, and sketching/painting. When not immersed in work, she can often be found tending to her garden (weather permitting) or engrossed in her sketching and painting projects.

See less

Articles from Susha

Methotrexate impairs immunogenicity of BNT162b2 SARS-CoV-2 vaccine in patients with immune-mediated inflammatory diseases

Researchers from Germany and the USA recently investigated the cellular and humoral immune responses of patients with IMIDs on immunomodulatory treatment to mRNA COVID-19 vaccines. The research is published on the medRxiv* preprint server.

19 May 2021

SARS-CoV-2 mRNA vaccine PTX-COVID19-B safe and highly immunogenic in preclinical study

COVID-19, the coronavirus disease of 2019, is one of the worst pandemics in human history. It emerged in December 2019 and is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nearly 164 million SARS-CoV-2 infections and 3.4 million deaths have been reported globally since the beginning of the pandemic, which is still raging in many countries.

18 May 2021

Evolutionary-spreading model predicts another devastating COVID-19 peak around July 2021

The emergence of this variant highlighted the uneven pace of mutation and selection of variants. New bioinformatics tools are the need of the hour to clarify this and confirm a dynamic evolution by tracking the mutation rates of the spike protein. It generally takes 1 – 6 months for current variants causing COVID-19 case peaks and deaths to survive the pressure of selection.

11 May 2021

Lab reports 1st instance of SARS-CoV-2 variants affecting antigen test performance

Researchers from the US recently determined the sensitivity of the Quidel Sofia SARS Antigen FIA test (Sofia 2). They found a high viral load specimen that tested negative repeatedly while using this antigen test. The study is published on the preprint server, medRxiv.

10 May 2021

Evidence that elevated blood glucose is a significant risk factor for severe COVID-19

The literature analysis pointed to elevated blood glucose levels as a leading facilitator in the progression of COVID-19. Evidence linking elevated glucose to various steps in the life cycle of the virus and presentation of COVID-19 symptoms were also found.

3 May 2021

Differential NK cell activity found to contribute to SARS-CoV-2 infection resistance

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people worldwide and is the leading cause of mortality in Brazil in 2020 as well as early 2021. Clinical manifestations of COVID-19 disease range from no symptoms and mild flu-like symptoms to severe cases leading to hospitalization and death.

3 May 2021

When can we stop wearing face masks?

Global rollout of vaccines to prevent coronavirus disease 2019 (COVID-19) is underway, with nine different vaccines approved for distribution by different countries. With four vaccines approved for distribution in the U.S., as of April 30, 2021, 29.9% of the U.S. population has now been fully vaccinated against SARS-CoV-2.

30 Apr 2021

Human to animal transmission of SARS-CoV-2 in households is common

Coronaviruses are seen in multiple mammalian species. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemic, is said to have passed to humans from a mammalian source and to have originated from an animal reservoir as a zoonotic pathogen.

29 Apr 2021

Neonates exposed to SARS-CoV-2 can sustain adverse health outcomes

The incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission from mothers to newborns appears low and may be linked to biological as well as social factors. However, studies focusing on the factors associated with neonatal viral testing outcomes.

27 Apr 2021

Single dose of J&J's Ad26.COV2.S vaccine effective against SARS-CoV-2 including in South Africa variant

One of these vaccines, the Ad26.COV2.S vaccine by Johnson & Johnson and Janssen, is a recombinant, replication-incompetent human adenovirus type 26 vector that encodes full-length SARS-CoV-2 spike protein in a prefusion-stabilized conformation.

26 Apr 2021